|
2024
|
Invention
|
Elp fusion proteins for controlled and sustained release.
The present disclosure provides pharma... |
|
2023
|
Invention
|
Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof. The present invent... |
|
|
Invention
|
Modified vasoactive intestinal peptides.
The present invention provides modified Vasoactive Inte... |
|
2022
|
Invention
|
Methods and compositions for treating muscle disease and disorders.
The present disclosure provi... |
|
2021
|
Invention
|
Fusion protein including glp-1 receptor agonist, and anti-oscar antibody and use thereof.
A fusi... |
|
|
Invention
|
Fusion protein including glp-1 receptor agonist and anti-oscar antibody, and use thereof. The pre... |
|
|
Invention
|
3-((8-((1h-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethinyl)-n-phenylbenzamide derivative, m... |
|
2020
|
Invention
|
Elp fusion proteins comprising parathyroid hormone for controlled and sustained release.
The pre... |
|
|
Invention
|
Methods and compositions for treating muscle disease and disorders. The present disclosure provid... |
|
2018
|
Invention
|
Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like pept... |
|
2016
|
Invention
|
Method for administering a sustained release formulation. The present invention provides pharmace... |
|
|
Invention
|
Use of modified vasoactive intestinal peptides in the treatment of hypertension. The present inve... |
|
|
Invention
|
Pharmaceutical composition for treating sarcopenia including glucagon-like peptide-1 receptor ago... |
|
|
Invention
|
Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor ag... |
|
2015
|
Invention
|
Elp fusion proteins for controlled and sustained release. The present disclosure provides pharmac... |
|
|
Invention
|
Methods and compositions for treating cystic fibrosis. The present disclosure provides a method o... |
|
|
Invention
|
Modified vasoactive intestinal peptides. The present invention provides modified Vasoactive Intes... |
|
2012
|
Invention
|
Systemic sustained release formulation comprising elastinlike peptide repeating sequence and pro... |
